trending Market Intelligence /marketintelligence/en/news-insights/trending/H4mn1H80M1HVDSq8dfKimA2 content esgSubNav
In This List

Masimo noninvasive blood oxygen measurement device approved by US FDA

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Masimo noninvasive blood oxygen measurement device approved by US FDA

Masimo Corp. said the U.S. Food and Drug Administration cleared its Rad-67 device combined with the Spot-check Next Generation SpHb monitoring system and Rainbow DCI sensor to measure the oxygen level in the blood.

Rad-67 is a pulse oximeter, a noninvasive device that measures the fraction of oxygen-carrying hemoglobin to total hemoglobin in the blood. The device also measures methemoglobin, stable oxidized hemoglobin that cannot transfer oxygen to the body's tissues, and a complex of carbon monoxide and hemoglobin called carboxyhemoglobin.

The device also allows for a historical review of the collected data, patient identification and wireless data transfer to electronic medical records. According to the company's March 25 press release, Rad-67 cannot be used for pregnant and pediatric patients as well as those with kidney disease. The device is not a replacement for laboratory blood testing, Masimo said.

The Irvine, Calif.-based healthcare company develops and markets noninvasive monitoring technologies.